This article was originally published in Start Up
Executive SummaryGenitope is using a novel gene expression technology in cancer immunotherapy. Starting with a tumor sample, it produces patient-specific idiotype antibodies which target B cell tumors and stimulate an immune response. The strategy is equivalent to that used in over a decade of clinical studies by Ron Levy of Stanford University, who encouraged Genitope founder Dan Denney to start the company.
Register for our free email digests: